Needham analyst Mike Matson named Zimmer Biomet his top pick for 2020 while raising his price target for the shares to $187 from $170. The analyst also added the shares to Needham's Conviction List. Matson expects the company's product cycle to drive further revenue growth acceleration, which should enable it to beat consensus and result in additional multiple expansion. Longer-term, he expects Zimmer to become a "margin story" and see its earnings power increase "significantly" as it reverses a multi-year decline in its operating margin. Further, portfolio management should reshape Zimmer into a higher-growth company, Matson tells investors in a research note.